Robert W. Baird assumed coverage on shares of Contineum Therapeutics (NASDAQ:CTNM - Free Report) in a report issued on Tuesday morning, Marketbeat reports. The brokerage issued an outperform rating and a $32.00 target price on the stock.
Separately, Royal Bank of Canada boosted their target price on shares of Contineum Therapeutics from $30.00 to $32.00 and gave the company an "outperform" rating in a research report on Wednesday, August 14th.
Check Out Our Latest Stock Report on CTNM
Contineum Therapeutics Price Performance
Shares of CTNM traded up $0.21 during trading hours on Tuesday, hitting $16.28. The company had a trading volume of 71,633 shares, compared to its average volume of 79,384. The business has a fifty day moving average of $18.00 and a 200-day moving average of $17.66. Contineum Therapeutics has a 12 month low of $13.27 and a 12 month high of $22.00.
Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.02). Equities analysts forecast that Contineum Therapeutics will post -2.04 EPS for the current year.
Hedge Funds Weigh In On Contineum Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of CTNM. Johnson & Johnson purchased a new stake in Contineum Therapeutics in the second quarter worth about $34,853,000. Perceptive Advisors LLC bought a new stake in Contineum Therapeutics in the 2nd quarter worth about $27,589,000. Versant Venture Management LLC bought a new position in shares of Contineum Therapeutics during the 2nd quarter valued at $16,169,000. Squarepoint Ops LLC purchased a new stake in shares of Contineum Therapeutics during the 2nd quarter valued at about $2,642,000. Finally, Driehaus Capital Management LLC bought a new position in Contineum Therapeutics in the second quarter worth approximately $1,174,000.
Contineum Therapeutics Company Profile
(
Get Free Report)
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
Further Reading
Before you consider Contineum Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Contineum Therapeutics wasn't on the list.
While Contineum Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
